LGD-4033, also known by the research name Ligandrol, has become one of the most studied selective androgen receptor modulators (SARMs) in the world. Originally developed by Ligand Pharmaceuticals and later licensed to Viking Therapeutics, it was designed to address muscle wasting conditions, osteoporosis, and age-related loss of lean mass. Today, researchers across physiology, sports science, and endocrinology labs continue to investigate its mechanisms, metabolite profiles, and systemic effects—making a concentrated 50mg/mL solution a compelling compound for advanced study protocols.
What Is LGD-4033?
LGD-4033 is a non-steroidal, orally bioavailable SARM that binds selectively to the androgen receptor (AR) with high affinity. Unlike testosterone and other anabolic steroids, SARMs like LGD-4033 are engineered to activate AR pathways in muscle and bone tissue while producing limited activity in the prostate and sebaceous glands. This tissue selectivity is what distinguishes the compound from classical anabolic agents and makes it a subject of ongoing clinical and translational research.
Chemically, LGD-4033 is classified as a fluorinated pyrrolidine derivative. Its high receptor-binding affinity—reportedly greater than testosterone—means even small concentrations can produce measurable androgenic effects in target tissues, which is why research into its dose-response relationship remains an active area of investigation.
Research Overview
According to PubMed, a notable 2022 case study published in Experimental Physiology by Cardaci et al. documented the effects of LGD-4033 co-administration with MK-677 on body composition and serum biomarkers. Over a 5-week observation period, a 25-year-old male subject using LGD-4033 at 10mg daily showed a 3.1% increase in total lean body mass and a 39.2% increase in one-repetition maximum leg press strength compared to non-users. The study also noted significant changes in lipid panels and liver enzymes, with most markers returning to baseline following cessation. (DOI: 10.1113/EP090741)
A 2021 analytical chemistry study from the German Sport University Cologne, published in Analytical and Bioanalytical Chemistry, mapped the elimination profile of LGD-4033 in human urine following micro-doses as low as 1µg. Researchers identified 15 phase I metabolites, with the M1 epimer ratio proving useful for estimating time-of-intake—a critical finding for anti-doping research contexts. (DOI: 10.1007/s00216-021-03740-7)
A 2024 case report published in Cureus by Labban et al. examined a 52-year-old male who presented with jaundice and elevated liver enzymes after three months of high-dose LGD-4033 use, representing a documented instance of drug-induced liver injury (DILI). Researchers concluded that off-label SARM use without clinical monitoring presents significant hepatotoxicity risk, underscoring the need for controlled research frameworks. (DOI: 10.7759/cureus.69601)
For community-level discussion and anecdotal reports from research enthusiasts, r/sarmssourcetalk and r/PEDs contain extensive threads cataloguing subjective observations from individuals who have self-administered the compound in non-clinical settings.
Potential Benefits Being Studied
- Lean mass accrual: Multiple observations suggest meaningful increases in appendicular and trunk lean body mass within short research windows.
- Strength augmentation: Case data indicates substantial improvements in compound lift performance metrics during administration periods.
- Tissue selectivity: Unlike classical androgens, LGD-4033’s receptor binding profile is designed to spare androgenic tissues outside of muscle and bone, which is the central hypothesis driving SARM development.
- Osteoporosis applications: Preclinical and early clinical data suggest potential utility in conditions involving bone mineral density loss, including age-related osteopenia.
- Muscle wasting conditions: LGD-4033 was originally developed for cachexia associated with cancer, chronic illness, and aging—research in these contexts continues in academic settings.
- Rapid half-life clearance: With an estimated half-life of 24–36 hours, LGD-4033 offers researchers a predictable pharmacokinetic window for structured observation protocols.
Dosage & Administration in Research Contexts
Published human data has used doses ranging from 0.1mg to 22mg daily in controlled Phase I trials. The phase I Ligand Pharmaceuticals trial—conducted by Basaria et al. (2013)—demonstrated dose-dependent lean mass gains at 0.1, 0.3, 1.0, and higher mg doses over 21 days, with the compound generally well-tolerated at lower ranges. In recreational research settings, doses between 5mg and 15mg per day are most frequently reported, typically across 6–10 week observation windows.
The 50mg/mL injectable concentration available through combatresearch.is allows researchers to work with precise, scalable concentrations across a range of experimental protocols. Proper reconstitution, sterile handling technique, and consistent dosing intervals are standard requirements for any controlled research environment. Researchers are advised to monitor hepatic enzymes and lipid panels at regular intervals throughout any observational study period.
Where to Find It
LGD-4033 at 50mg/mL concentration in a 10mL vial is available for research purposes at combatresearch.is. The site maintains consistent compound specifications suitable for structured laboratory and observational research use.
Conclusion
LGD-4033 remains one of the most pharmacologically characterized SARMs in the research landscape. Its defined receptor selectivity, documented metabolite profile, and growing body of case-study data make it a compound of genuine scientific interest across muscle physiology, endocrinology, and anti-doping research. As with all investigational compounds, responsible handling, biomarker monitoring, and compliance with institutional research guidelines are essential. The 50mg/mL formulation provides the concentration flexibility that serious research protocols demand.
Disclaimer: This article is intended solely for educational and informational purposes. LGD-4033 is not approved by the FDA for human use. It is sold exclusively for research purposes. This content does not constitute medical advice, diagnosis, or treatment. Researchers should comply with all applicable laws and institutional guidelines governing the use of investigational compounds.
